Glycotest, Inc. is focused on developing innovative, non-invasive blood tests aimed at the early detection of liver cancers, specifically hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), as well as liver fibrosis and cirrhosis. Their technology leverages the unique chemistry of glycoprotein fucosylation, which is characterized by abnormal levels of the monosaccharide fucose on certain serum glycoproteins. By measuring both the quantity of fucose and the specific patterns of fucosylated glycoproteins, Glycotest aims to provide critical information regarding the likelihood of serious liver diseases. This approach is particularly significant given the rising incidence of liver cancer, especially in populations at risk due to chronic liver conditions such as viral hepatitis and non-viral hepatitis linked to obesity.

The proprietary biomarkers and assays developed by Glycotest are designed to outperform traditional serum biomarkers like alpha-fetoprotein (AFP), which is often insufficient for early-stage detection of HCC. Glycotest's blood tests utilize standard blood samples to create algorithm-driven biomarker panels that can identify early-stage liver diseases, potentially improving patient outcomes by facilitating timely intervention. The company’s technology not only addresses the urgent need for effective early detection methods but also aims to provide a more comprehensive understanding of liver health, thereby revolutionizing care for individuals at risk of liver-related diseases.

United States

Glycotest is Creating the New Clinical Standard for Early Diagnosis and Surveillance of Liver Cancer

Glycotest, Inc.

Company Details